Independent fund research. Built on SEC filings.

How we research funds

ETF · Leveraged & Inverse · Direxion

Direxion Daily S&P Biotech Bear 3X ETF (LABD)

Ticker LABD · Index fund · · Holdings as of Jul 31, 2026

Expense ratio
1.07%$107/yr per $10k
5-yr return
−37.7%annualized
1-yr return
−70.0%as of Dec 2025
Net assets
$54.2Mall share classes
Holdings
10

Bottom line

Is LABD a good fund? The bottom line

LABD is an index leveraged & inverse ETF from Direxion.

It charges 1.07% — about $107 a year on every $10,000 invested, cheaper than 64% of leveraged & inverse funds we track.

It returned −70.0% over one year, −37.7% a year over five years, −54.4% a year over ten (as of Dec 31, 2025, per its prospectus).

With $54.2 million in net assets and 10 holdings, its largest position is Goldman Financial (52.7%) and the top 10 make up 125% of the portfolio.

What to watch

  • 5-year return in the bottom quarter of its category
  • Concentrated: top 10 holdings are 125% of assets

Updated Nov 19, 2026

What LABD invests in

The Fund seeks daily investment results, before fees and expenses, of 300% of the inverse (or opposite) of the daily performance of the Index. The Fund does not seek to achieve its stated investment objective for a period of time different than a trading day.

"The Index is provided by S&P Dow Jones Indices (the Index Provider) and includes domestic companies from the biotechnology industry. The Index is a modified equal-weighted index that is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards (GICS). GICS classifications are determined primarily based on a companys revenues, however, earnings and market perception are also considered by GICS. The Index consists of constituents of the S&P Total Market Index (S&P TMI) that belong to the GICS biotechnology sub-industry that satisfy the following criteria: (1) have a float-adjusted market capitalization above $300 million with a float-adjusted liquidity ratio (defined by dollar value traded over the previous 12 months divided by the float-adjusted market capitalization as of the Index rebalancing reference date) above 50%…

From the fund's prospectus (filed Mar 3, 2026).

LABD performance

Fund calendar-year total returns, 2016–2025 2016: −39.1%; 2017: −75.6%; 2018: −7.1%; 2019: −70.6%; 2020: −89.8%; 2021: +2.1%; 2022: −32.9%; 2023: −41.6%; 2024: −21.6%; 2025: −70.0% −39% 2016 −76% 2017 −7% 2018 −71% 2019 −90% 2020 +2% 2021 −33% 2022 −42% 2023 −22% 2024 −70% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
LABD−70.0%−37.7%−54.4%
Leveraged & Inverse median−7.7%−11.8%−13.5%

Source: Fund prospectus, as of Dec 31, 2025

Full LABD performance history →

What LABD costs

On a $10,000 investment, LABD's 1.07% expense ratio costs about $107 a year. The prospectus estimates $1,316 in total costs over 10 years (assuming 5% annual returns). The median leveraged & inverse fund charges 1.31%.

See the full LABD fee table →

LABD top 10 holdings

#Holding% of fund
1Goldman Financial52.74%
2Dreyfus40.47%
3Goldman Sachs Liq Es Fd A26.30%
4Dreyfus18.03%
5N/a2.98%
6N/a1.43%
7N/a-1.55%
8N/a-4.11%
9N/a-4.88%
10N/a-6.37%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 125% of the fund. See all top 25 holdings and asset mix →

Alternatives to LABD

More funds like LABD →

LABD FAQ

What is the expense ratio of LABD?
LABD's expense ratio is 1.07%, which works out to about $107 a year for every $10,000 invested. The prospectus estimates total costs of $1,316 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is LABD a good investment?
It depends on your goals, but the data points to: 5-year return in the bottom quarter of its category; concentrated: top 10 holdings are 125% of assets. This is general information, not personalized advice.
What does LABD hold?
LABD's largest holdings are Goldman Financial (52.7%), Dreyfus (40.5%), Goldman Sachs Liq Es Fd A (26.3%), Dreyfus (18.0%), N/a (3.0%). It holds 10 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
What is LABD's 5-year return?
LABD returned −37.7% a year over the five years ending Dec 31, 2025, and −54.4% a year over ten years. Past performance does not guarantee future results.
Who manages LABD?
LABD is offered by Direxion through Direxion Shares ETF Trust.